Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
2.
Tob Induc Dis ; 19: 64, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34413719

RESUMO

INTRODUCTION: To achieve the Sustainable Development Goals (SDGs) target 2030, the United Nations (UN) endorsed tobacco use reduction, which is essential in decreasing unnecessary deaths caused by tobacco-induced disease. This study investigates the association between tobacco use and Human Papillomavirus (HPV) infection in clinically normal uterine cervix populations from the SDGs perspective. METHODS: This study is a 7-year cross-sectional study of a clinically normal uterine cervix population, based on negative Visual Inspection of Acetic Acid (VIA). Subjects were recruited consecutively from the medical records of several public and private health providers in Jakarta. The Statistical Product and Service Solutions (SPSS) for Windows version 20.0 were used to analyze the data. RESULTS: A total of 1397 negative VIA subjects were collected, consisting of 4.9% (69/1397) tobacco users, and 95.1% (1328/1397) non-users. HPV-DNA positive were 4.3% (3/69) in the tobacco user group and 3.7% (49/1328) in the non-user group. Statistical analysis showed unadjusted OR was 1.19 (95% CI: 0.36-3.91, p=0.778) and adjusted OR was 1.18 (95% CI: 0.36-3.89, p=0.786). High-risk HPV (hrHPV) infections of tobacco and non-tobacco users' groups were found in 2/3 and 27/49 (55.1%), respectively. CONCLUSIONS: This study showed an insignificant statistical association between tobacco use and HPV infection in normal uterine cervix. However, the proportion of hrHPV infection was higher in tobacco users than non-users. From the SDGs perspective, cervical cancer is closely related to tobacco use and poverty. Further study is needed to support this result and evaluate other co-factor role-related cervical cancer history to achieve SDGs in 2030.

3.
Arch Gynecol Obstet ; 298(5): 1001-1007, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30218184

RESUMO

PURPOSE: To evaluate the effectiveness of ovarian transposition (OT) prior to radiation therapy (RT) and to evaluate the effect of age on ovarian survival (OS) after OT. METHODS: We performed a retrospective control study, with women (aged < 45 years) who underwent OT prior to pelvic radiation, versus women diagnosed with cervical cancer and treated with hysterectomy/trachelectomy and radiation therapy. All women were treated between 1989 and 2010. The 5 years OS rate was calculated, with a sub-analysis for age (25-30; 31-35 and 36-40 years). Ovarian failure was defined as climacteric complaints (with or without starting hormone replacement therapy) and/or laboratory measurements (FSH > 40 IU/L and/or estradiol < 100 pmol/L), or bilateral salpingo oophorectomy. Women were censored at recurrence. RESULTS: Twenty-seven women after OT and 29 controls were included. The radiation dose was 44.8 Gy (25.0-63.0 Gy) and 46.3 Gy (45.0-50.0 Gy), respectively. The 5-year ovarian survival rate was 60.3% versus controls 0% (p < 0.001 95% CI 3.48-11.50). Despite the decrease in ovarian survival after OT with increasing age, in all age groups (25-30, 30-35 and 35-40) ovarian survival after OT was significantly better compared to women without OT (p = 0.001; p = 0.004 and p = 0.000, respectively). Neither intra-vaginal radiation therapy of concomitant chemotherapy in addition to pelvic radiation significantly altered ovarian survival. CONCLUSIONS: Our data shows that ovarian transposition prior to pelvic radiation is effective in women until the age of 35 years and needs to be discussed in patients aged 36-40 years.


Assuntos
Procedimentos Cirúrgicos em Ginecologia/métodos , Ovário/efeitos da radiação , Insuficiência Ovariana Primária/prevenção & controle , Qualidade de Vida , Lesões por Radiação/prevenção & controle , Neoplasias do Colo do Útero/radioterapia , Adulto , Fatores Etários , Carcinoma de Células Escamosas/radioterapia , Estudos de Casos e Controles , Feminino , Preservação da Fertilidade/métodos , Humanos , Histerectomia , Recém-Nascido , Menopausa , Insuficiência Ovariana Primária/etiologia , Estudos Retrospectivos , Taxa de Sobrevida , Traquelectomia , Neoplasias do Colo do Útero/cirurgia
4.
Gynecol Oncol ; 148(1): 189-196, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-29113722

RESUMO

OBJECTIVE: To investigate the prevalence of somatic mutations in Indonesian cervical carcinoma patients in the context of histology and human papillomavirus (HPV) type. METHODS: In total 174 somatic hot-spot mutations in 13 genes were analyzed by mass spectrometry in 137 Indonesian cervical carcinomas. RESULTS: In 66/137 tumors (48%) 95 mutations were identified. PIK3CA was most frequently mutated (24%), followed by FBXW7 (7%), CTNNB1 (6%), and PTEN (6%). In squamous cell carcinomas more often multiple mutations per sample (p=0.040), and more PIK3CA (p=0.039) and CTNNB1 (p=0.038) mutations were detected compared to adenocarcinomas. PIK3CA mutations were associated with HPV 16 positivity, CDKN2A mutations with HPV 52 positivity, and, interestingly, PTEN mutations with HPV negativity. Balinese tumor samples more often carried multiple mutations (p=0.019), and more CTNNB1, CDKN2A, and NRAS mutations compared to Javanese tumor samples. CONCLUSIONS: Potentially targetable somatic mutations occurred in 48% of Indonesian cervical carcinomas. The landscape of mutations is predominated by mutations concerning the PI3K pathway, and we prompt for more research on developing therapies targeting this pathway, explicitly for the more advanced stage cervical carcinoma patients.


Assuntos
Mutação , Fosfatidilinositol 3-Quinases/metabolismo , Neoplasias do Colo do Útero/enzimologia , Neoplasias do Colo do Útero/genética , Adulto , Classe I de Fosfatidilinositol 3-Quinases/genética , Proteína 7 com Repetições F-Box-WD/genética , Feminino , Humanos , Indonésia , Espectrometria de Massas , Pessoa de Meia-Idade , Análise Multivariada , PTEN Fosfo-Hidrolase/genética , Transdução de Sinais , Neoplasias do Colo do Útero/patologia , Neoplasias do Colo do Útero/virologia , beta Catenina/genética
5.
Clin Case Rep ; 5(9): 1503-1509, 2017 09.
Artigo em Inglês | MEDLINE | ID: mdl-28878914

RESUMO

We report a novel KRT13 germ line variant that causes white sponge nevus (WSN) with mucosal dysplasia. Genital, vaginal, and cervical WSN were observed in four female patients, of whom two had premalignant cervical lesions at young age. Two of the 12 patients with oral WSN developed oral squamous cell carcinoma.

6.
J Cancer Prev ; 22(2): 103-107, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28698864

RESUMO

BACKGROUND: Cervical cancer is still the second most frequent cancer among Indonesian women, thus screening program is still critically important to prevent it. Visual inspection with acetic acid (VIA) was introduced as a method which is most suitable with Indonesia's condition compared with the other screening methods. The Female Cancer Program from Jakarta Regional collaborated with Leiden University in 2007 to 2011 has done cervical cancer screening using VIA method, involving 25,406 women spreading across several primary health centers in Jakarta. By using these data, we found out the prevalence, age distribution, and risk factor of VIA positive in Jakarta as a basis to predict the budget and logistics for the next cervical cancer screening and to do an advocating to the Jakarta's government. METHODS: A secondary data analysis was conducted from several areas in Jakarta from 2007 to 2011. VIA test was used as the screening method, and performed by doctors and midwives with technical supervision by gynecologists. RESULTS: From 25,406 women, there were 1,192 cases (4.7%) of VIA test positive. The risk factors that can significantly influence the result of VIA positive were number of marriage, parity, smoking habits, and the use of hormonal contraception with OR 1.51, 1.85, 1.95, and 0.68, respectively. CONCLUSIONS: Prevalence of VIA test-positive is 4.7% in Jakarta population. The findings of precancerous lesions and cervical cancers are not only between thirty and fifty years old, but also below the thirty years old and after fifty years old. We suggest that VIA test should be performed to all reproductive age and elder women who are not screened yet.

7.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-173850

RESUMO

BACKGROUND: Cervical cancer is still the second most frequent cancer among Indonesian women, thus screening program is still critically important to prevent it. Visual inspection with acetic acid (VIA) was introduced as a method which is most suitable with Indonesia's condition compared with the other screening methods. The Female Cancer Program from Jakarta Regional collaborated with Leiden University in 2007 to 2011 has done cervical cancer screening using VIA method, involving 25,406 women spreading across several primary health centers in Jakarta. By using these data, we found out the prevalence, age distribution, and risk factor of VIA positive in Jakarta as a basis to predict the budget and logistics for the next cervical cancer screening and to do an advocating to the Jakarta's government. METHODS: A secondary data analysis was conducted from several areas in Jakarta from 2007 to 2011. VIA test was used as the screening method, and performed by doctors and midwives with technical supervision by gynecologists. RESULTS: From 25,406 women, there were 1,192 cases (4.7%) of VIA test positive. The risk factors that can significantly influence the result of VIA positive were number of marriage, parity, smoking habits, and the use of hormonal contraception with OR 1.51, 1.85, 1.95, and 0.68, respectively. CONCLUSIONS: Prevalence of VIA test-positive is 4.7% in Jakarta population. The findings of precancerous lesions and cervical cancers are not only between thirty and fifty years old, but also below the thirty years old and after fifty years old. We suggest that VIA test should be performed to all reproductive age and elder women who are not screened yet.


Assuntos
Feminino , Humanos , Ácido Acético , Distribuição por Idade , Orçamentos , Anticoncepção , Casamento , Programas de Rastreamento , Métodos , Tocologia , Organização e Administração , Paridade , Prevalência , Fatores de Risco , Fumaça , Fumar , Estatística como Assunto , Neoplasias do Colo do Útero
8.
Oncotarget ; 7(18): 26192-205, 2016 May 03.
Artigo em Inglês | MEDLINE | ID: mdl-27028855

RESUMO

BACKGROUND: Vulvar cancer treatment is mostly curative, but also has high morbidity rates. In a search for markers that can identify patients at risk of metastases, we investigated the prognostic value of L1-cell adhesion molecule (L1CAM) in large series of vulvar squamous cell carcinomas (VSCCs). L1CAM promotes cell motility and is an emerging prognostic factor for metastasis in many cancer subtypes. RESULTS: L1CAM expression was observed at the invasive front or in spray-patterned parts of 17% of the tumours. L1CAM-positive tumours expressed vimentin more often, but L1CAM expression was not associated with TP53 or CTNNB1 mutations. Five-year survival was worse for patients with L1CAM expression (overall survival 46.1% vs 63.6%, P=.014, disease specific survival 63.8% vs 80.0%, P=.018). Multivariate analysis indicates L1CAM expression as an independent prognostic marker (HR 2.9, 95% CI 1.10-7.68). An in vitro spheroid invasion assay showed decreased invasion of L1CAM-expressing VSCC spindle cells after treatment with L1CAM-neutralising antibodies. METHODS: Paraffin-embedded tumour tissue from two cohorts (N=103 and 245) of primary VSCCs were stained for L1CAM, vimentin and E-cadherin. Patients of the first cohort were tested for human papilloma virus infection and sequenced for TP53 and CTNNB1 (ß-catenin) mutations. The expression of L1CAM was correlated to clinical characteristics and patient survival. CONCLUSION: This is the first study to show high L1CAM-expression at the infiltrating margin of VSCC's. L1CAM-expressing VSCCs had a significantly worse prognosis compared to L1CAM-negative tumours. The highest expression was observed in spindle-shaped cells, where it might be correlated to their invasive capacity.


Assuntos
Biomarcadores Tumorais/metabolismo , Carcinoma de Células Escamosas/patologia , Recidiva Local de Neoplasia/patologia , Molécula L1 de Adesão de Célula Nervosa/metabolismo , Neoplasias Vulvares/patologia , Idoso , Carcinoma de Células Escamosas/metabolismo , Feminino , Humanos , Recidiva Local de Neoplasia/metabolismo , Prognóstico , Taxa de Sobrevida , Neoplasias Vulvares/metabolismo
9.
J Psychosom Obstet Gynaecol ; 36(4): 155-60, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26328772

RESUMO

OBJECTIVE: To provide a current account of women's sexual and reproductive health and rights (SRHR) in Ghana (West Africa), a priority area in achieving the World Health Organization's Millennium Development Goals. METHOD: The study was observational. Three-hundred ninety Ghanaian women attending cervical cancer screening were surveyed about their SRHR. The data were analyzed with chi-squared test (p ≤ 0.05, two-sided). RESULTS: 22.1% had a life-time history of non-consensual sexual experience and 55.4% a previous history of abortion, mostly using services of a registered clinic (68.5%). Experience of sexual violence increased life-time risk of abortion (p = 0.018). The overall use of contraceptives was high (>60%); however, condom use during sexual intercourse with a new partner was low (23%), even among the highly educated women (32.7%) and women who stated to have received information on the risks and benefits of condom use (26.0%). Although condom use among the highly educated women was low, it was still 2 times higher than among the lower educated women, 15.7% (p < 0.001). There was also less condom use among the women with multiple sexual partners compared to single-partnered women (p = 0.001). CONCLUSION: More than a decade after the inception of the Millennium Development Goals, there is still work to be done in Ghana, especially on education and sexual violence.


Assuntos
Comportamento Contraceptivo/estatística & dados numéricos , Saúde Reprodutiva/estatística & dados numéricos , História Reprodutiva , Direitos da Mulher , Adulto , Feminino , Gana/epidemiologia , Humanos , Pessoa de Meia-Idade , Avaliação das Necessidades , Comportamento Sexual/estatística & dados numéricos , Parceiros Sexuais , Fatores Socioeconômicos , Organização Mundial da Saúde
10.
PLoS One ; 10(7): e0133670, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26197069

RESUMO

INTRODUCTION: Squamous cell carcinoma (SCC), adenocarcinoma (AC), and adenosquamous carcinoma (ASC) are the most common histological subtypes of cervical cancer. Differences in the somatic mutation profiles of these subtypes have been suggested. We investigated the prevalence of somatic hot-spot mutations in three well-defined cohorts of SCC, AC, and ASC and determined the additional value of mutation profiling in predicting disease outcome relative to well-established prognostic parameters. MATERIALS AND METHODS: Clinicopathological data were collected for 301 cervical tumors classified as SCC (n=166), AC (n=55), or ASC (n=80). Mass spectrometry was used to analyze 171 somatic hot-spot mutations in 13 relevant genes. RESULTS: In 103 (34%) tumors, 123 mutations were detected (36% in SCC, 38% in AC, and 28% in ASC), mostly in PIK3CA (20%) and KRAS (7%). PIK3CA mutations occurred more frequently in SCC than AC (25% vs. 11%, P=0.025), whereas KRAS mutations occurred more frequently in AC than SCC (24% vs. 3%, P<0.001) and ASC (24% vs. 3%, P<0.001). A positive mutation status correlated with worse disease-free survival (HR 1.57, P=0.043). In multivariate analysis, tumor diameter, parametrial infiltration, and lymph node metastasis, but not the presence of a somatic mutation, were independent predictors of survival. CONCLUSION: Potentially targetable somatic mutations occurred in 34% of cervical tumors with different distributions among histological subtypes. Precise classification of cervical carcinomas in combination with mutation profiling is valuable for predicting disease outcome and may guide the development and selection of tumor-specific treatment approaches.


Assuntos
Adenocarcinoma/genética , Carcinoma de Células Escamosas/genética , Mutação , Neoplasias do Colo do Útero/genética , Adenocarcinoma/classificação , Adenocarcinoma/patologia , Adulto , Proteínas Adaptadoras de Sinalização CARD , Carcinoma de Células Escamosas/classificação , Carcinoma de Células Escamosas/patologia , Classe I de Fosfatidilinositol 3-Quinases , Proteínas do Citoesqueleto/genética , Feminino , Humanos , Pessoa de Meia-Idade , Metástase Neoplásica , Fosfatidilinositol 3-Quinases/genética , Prognóstico , Proteínas Proto-Oncogênicas p21(ras)/genética , Neoplasias do Colo do Útero/classificação , Neoplasias do Colo do Útero/patologia
11.
PLoS One ; 10(6): e0129766, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26110901

RESUMO

OBJECTIVE: In ovarian cancer, two of the most important prognostic factors for survival are completeness of staging and completeness of cytoreductive surgery. Therefore, intra-operative visualization of tumor lesions is of great importance. Preclinical data already demonstrated tumor visualization in a mouse-model using near-infrared (NIR) fluorescence imaging and indocyanine green (ICG) as a result of enhanced permeability and retention (EPR). The aim of this study was to determine feasibility of intraoperative ovarian cancer metastases imaging using NIR fluorescence imaging and ICG in a clinical setting. METHODS: Ten patients suspected of ovarian cancer scheduled for staging or cytoreductive surgery were included. Patients received 20 mg ICG intravenously after opening the abdominal cavity. The mini-FLARE NIR fluorescence imaging system was used to detect NIR fluorescent lesions. RESULTS: 6 out of 10 patients had malignant disease of the ovary or fallopian tube, of which 2 had metastatic disease outside the pelvis. Eight metastatic lesions were detected in these 2 patients, which were all NIR fluorescent. However, 13 non-malignant lesions were also NIR fluorescent, resulting in a false-positive rate of 62%. There was no significant difference in tumor-to-background ratio between malignant and benign lesions (2.0 vs 2.0; P=0.99). CONCLUSIONS: This is the first clinical trial demonstrating intraoperative detection of ovarian cancer metastases using NIR fluorescence imaging and ICG. Despite detection of all malignant lesions, a high false-positive rate was observed. Therefore, NIR fluorescence imaging using ICG based on the EPR effect is not satisfactory for the detection of ovarian cancer metastases. The need for tumor-specific intraoperative agents remains. TRIAL REGISTRATION: ISRCTN Registry ISRCTN16945066.


Assuntos
Metástase Neoplásica/diagnóstico , Neoplasias Ovarianas/cirurgia , Adulto , Idoso , Feminino , Corantes Fluorescentes , Humanos , Verde de Indocianina , Pessoa de Meia-Idade , Monitorização Intraoperatória , Imagem Óptica/métodos , Neoplasias Ovarianas/metabolismo , Neoplasias Ovarianas/patologia , Permeabilidade
12.
Int J Gynecol Cancer ; 25(6): 1086-93, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25768079

RESUMO

OBJECTIVE: Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has recently been introduced to improve the sentinel lymph node (SLN) procedure. Several optical tracers have been successfully tested. However, the optimal tracer formulation is still unknown. This study evaluates the performance of ICG-technetium-99m (99mTc)-nanocolloid in relation to 2 most commonly used ICG-based formulas during SLN biopsy in vulvar cancer. METHODS AND MATERIALS: Twelve women who planned to undergo SLN biopsy for stage I vulvar cancer were prospectively included. Sentinel lymph node mapping was performed using the dual-modality radioactive and NIR fluorescence tracer ICG-99mTc-nanocolloid. All patients underwent combined SLN localization using NIR fluorescence and the (current) gold standard using blue dye and radioactive guidance. RESULTS: In all 12 patients, at least 1 SLN was detected during surgery. A total of 21 lymph nodes (median 2; range, 1-3) were resected. Median time between skin incision and first SLN detection was 8 (range, 1-22) minutes. All resected SLNs were both radioactive and fluorescent, although only 13 (62%) of 21 SLNs stained blue. Median brightness of exposed SLNs, expressed as signal-to-background ratio, was 5.4 (range, 1.8-11.8). Lymph node metastases were found in 3 patients. CONCLUSIONS: Near-infrared fluorescence-guided SLN mapping is feasible and outperforms blue dye staining. Premixing ICG with 99mTc-nanocolloid provides real-time intraoperative imaging of the SN and seems to be the optimal tracer combination in terms of intraoperative detection rate of the SN (100%). Moreover, ICG-99mTc-nanocolloid allows the administration of a 5-times lower injected dose of ICG (compared with ICG and ICG absorbed to human serum albumin) and can be injected up to 20 hours before surgery.


Assuntos
Biópsia Guiada por Imagem/métodos , Verde de Indocianina/farmacocinética , Biópsia de Linfonodo Sentinela , Agregado de Albumina Marcado com Tecnécio Tc 99m/farmacocinética , Neoplasias Vulvares/diagnóstico por imagem , Neoplasias Vulvares/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Corantes/farmacocinética , Feminino , Fluorescência , Seguimentos , Humanos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Estudos Prospectivos , Cintilografia , Compostos Radiofarmacêuticos/farmacocinética , Espectroscopia de Luz Próxima ao Infravermelho , Distribuição Tecidual
13.
Gynecol Oncol ; 135(1): 149-55, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25072932

RESUMO

BACKGROUND: Two etiologic pathways of vulvar cancer are known, a human papillomavirus (HPV)- and a TP53-associated route, respectively, but other genetic changes may also play a role. Studies on somatic mutations in vulvar cancer other than TP53 are limited in number and size. In this study, we investigated the prevalence of genetic mutations in 107 vulvar squamous cell carcinomas (VSCCs). METHODS: A total of 107 paraffin-embedded tissue samples of primarily surgically treated VSCCs were tested for HPV infection and screened for mutations in 14 genes (BRAF, CDKN2A(p16), CTNNB1, FBXW7, FGFR2, FGFR3, FOXL2, HRAS, KRAS, NRAS, PIK3CA, PPP2R1A, PTEN, and TP53) using Sanger sequencing and mass spectrometry. RESULTS: Mutations were detected in 7 genes. Of 107 VSCCs, 66 tumors (62%) contained at least one mutation (TP53=58, CDKN2A(p16)=14, HRAS=10, PIK3CA=7, PPP2R1A=3, KRAS=1, PTEN=1). Mutations occurred most frequently in HPV-negative samples. Five-year survival was significantly worse for patients with a mutation (47% vs 59%, P=.035), with a large effect from patients carrying HRAS-mutations. CONCLUSION: Somatic mutations were detected in 62% of VSCCs. As expected, HPV infection and TP53-mutations play a key role in the development of VSCC, but CDKN2A(p16), HRAS, and PIK3CA-mutations were also frequently seen in HPV-negative patients. Patients with somatic mutations, especially HRAS-mutations, have a significantly worse prognosis than patients lacking these changes, which could be of importance for the development of targeted therapy.


Assuntos
Carcinoma de Células Escamosas/genética , Genes p16 , Mutação , Proteínas Proto-Oncogênicas p21(ras)/genética , Neoplasias Vulvares/genética , Idoso , Carcinoma de Células Escamosas/mortalidade , Inibidor p16 de Quinase Dependente de Ciclina , Feminino , Humanos , Proteínas de Neoplasias , Taxa de Sobrevida , Neoplasias Vulvares/mortalidade
14.
Int J Gynecol Cancer ; 24(4): 735-43, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24651626

RESUMO

OBJECTIVES: Standard treatment in early-stage cervical cancer is a radical hysterectomy (RH) with pelvic lymphadenectomy. In women who wish to preserve fertility radical vaginal trachelectomy has been proposed; however, this is not feasible in larger tumors, and nerve-sparing surgery is not possible. Nerve-sparing radical abdominal trachelectomy (NSRAT) overcomes these disadvantages. METHODS: Case-control study of women with early-stage cervical cancer (International Federation of Gynecology and Obstetrics IA2-IB) submitted to NSRAT from 2000 until 2011. Women submitted to nerve-sparing RH with early-stage cervical cancer were included as control subjects. RESULTS: Twenty-eight patients and 77 control subjects were included. Neoadjuvant chemotherapy was administered in 3 women before NSRAT because the linear extension was or exceeded 40 mm. Local recurrence rate was 3.6% (95% confidence interval [CI], 0.00-10.6) in the NSRAT group compared with 7.8% (95% CI, 1.7-13.9) in the control group (P = 0.44). No significant difference was found between both groups regarding disease-free survival and survival. The overall pregnancy rate was 52.9% (95% CI, 28.7%-77.2%). The mean follow-up was 47.3 months (range, 6-122 months) for NSRAT and 51.8 months (11-129.6 months) for nerve-sparing RH. CONCLUSIONS: Nerve-sparing radical abdominal trachelectomy seems safe and effective in women with early-stage cervical cancer who wish to preserve fertility. Respective women should be informed about this treatment option, especially if the tumor is too large for radical vaginal trachelectomy.


Assuntos
Abdome/cirurgia , Procedimentos Cirúrgicos em Ginecologia/métodos , Histerectomia , Recidiva Local de Neoplasia/cirurgia , Sistema Nervoso , Tratamentos com Preservação do Órgão/métodos , Neoplasias do Colo do Útero/cirurgia , Abdome/patologia , Adenocarcinoma/patologia , Adenocarcinoma/cirurgia , Adulto , Idoso , Carcinoma Adenoescamoso/patologia , Carcinoma Adenoescamoso/cirurgia , Carcinoma de Células Escamosas/patologia , Carcinoma de Células Escamosas/cirurgia , Estudos de Casos e Controles , Colo do Útero/patologia , Colo do Útero/cirurgia , Estudos de Viabilidade , Feminino , Preservação da Fertilidade , Seguimentos , Humanos , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Gravidez , Prognóstico , Estudos Prospectivos , Neoplasias do Colo do Útero/patologia , Adulto Jovem
15.
J Psychosom Obstet Gynaecol ; 34(3): 129-32, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23915206

RESUMO

PURPOSE: The aim of this study was to assess oncologists' practice and attitudes regarding treatment-related infertility and fertility preservation in female cancer patients of reproductive age. PARTICIPANTS AND METHODS: Recruitment letters with a 7-item questionnaire were sent to 454 oncologists. RESULTS: Two hundred and six of the 454 physicians (45%) responded and 96 questionnaires were used for analysis. The sample included 28 (29%) gynaecologists, 22 (23%) medical oncologists, 19 (20%) surgeons, 16 (17%) radiotherapists and 11 (12%) haematologists. Sixty-two percent of the physicians took action to protect ovarian function before or during gonadotoxic therapy. The most important reason for not offering fertility preservation was "factors concerning the disease". About one-third of the oncologists did not discuss fertility issues. Nearly half of the physicians (43%) would offer fertility preservation options, if they were standardized. High importance was given by almost all physicians (96%) to quality of life in general after gonadotoxic therapy and to the provision of information about fertility preservation options (81%). However, when asked about the importance of infertility after a malignancy, a smaller majority of the physicians (59%) gave it high importance. CONCLUSION: Most physicians considered infertility to be a major issue to be discussed, and most intended to take action to protect ovarian function before or during gonadotoxic therapy.


Assuntos
Atitude do Pessoal de Saúde , Preservação da Fertilidade/psicologia , Conhecimentos, Atitudes e Prática em Saúde , Infertilidade/etiologia , Neoplasias/terapia , Padrões de Prática Médica , Adulto , Feminino , Pesquisas sobre Atenção à Saúde , Humanos , Infertilidade/psicologia , Pessoa de Meia-Idade , Neoplasias/complicações , Neoplasias/psicologia , Países Baixos , Projetos Piloto , Qualidade de Vida , Inquéritos e Questionários
16.
J Transl Med ; 10: 184, 2012 Sep 04.
Artigo em Inglês | MEDLINE | ID: mdl-22947189

RESUMO

BACKGROUND: Cervical cancer is the third most common cancer in women worldwide. The most common histopathological subtype is cervical squamous cell carcinoma (SCC, 75-80%), followed by adenocarcinoma (AC) and adenosquamous carcinoma (ASC; together 15-20%). Rising incidence rates of AC have been observed relative and absolute to SCC and evidence is accumulating that cervical AC is a distinct clinical entity. Cervical SCC, ASC, and AC are caused by a persistent infection with high-risk human papillomavirus (HPV) and failed control of the immune system plays a pivotal role in the carcinogenesis of all three histopathological subtypes. Human leukocyte antigen E (HLA-E), a non-classical HLA class Ib molecule, plays an important role in immune surveillance and immune escape of virally infected cells. In this study we investigated HLA-E expression in three well-defined cohorts of cervical AC, ASC, and SCC patients, and determined whether HLA-E expression was associated with histopathological parameters and patient survival. METHODS AND RESULTS: HLA-E expression was assessed by immunohistochemistry on formalin-fixed, paraffin-embedded tissue sections of 79 SCC, 38 ASC, and 75 AC patients. All patients included were International Federation of Gynaecology and Obstetrics stage I-II and underwent radical hysterectomy with lymphadenectomy as primary treatment. Significant differences between the histopathological subgroups were detected for age distribution, HPV positivity, HPV type distribution, tumour size, tumour infiltration depth, lymph-vascular space invasion, and adjuvant radiotherapy. High expression of HLA-E was found in 107/192 (56%) cervical carcinomas, with significantly more overexpression in cervical AC compared to SCC and ASC (37/79 SCC, 18/38 ASC, and 52/75 AC; P = 0.010). High HLA-E expression in cervical AC was associated with favourable long term disease-specific and recurrence-free survival (P = 0.005 and P = 0.001, respectively). CONCLUSION: High expression of HLA-E occurred in the majority of all histopathological subtypes of cervical cancer; especially in cervical AC. High HLA-E expression in cervical AC was associated with improved patient survival. This study also highlights the importance of careful evaluation of cervical carcinomas to distinguish histopathological subtypes. In the future, insight into the biological behaviour and distinct molecular carcinogenetic processes of the AC, ASC, and SCC subtypes may contribute to the development of more tumour-specific treatment strategies.


Assuntos
Adenocarcinoma/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Neoplasias do Colo do Útero/imunologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Imuno-Histoquímica , Pessoa de Meia-Idade , Taxa de Sobrevida , Antígenos HLA-E
17.
Gynecol Oncol ; 127(1): 126-30, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22796548

RESUMO

OBJECTIVE: Near-infrared fluorescence imaging using indocyanine green (ICG) has recently been introduced as a novel technique for sentinel lymph node (SLN) mapping in early-stage cervical cancer. Although preclinical research has shown that ICG adsorbed to human serum albumin (ICG:HSA) improves its performance, the need for HSA has not yet been confirmed in cervical cancer patients. The current randomized study aims to determine whether ICG:HSA offers advantages over using ICG alone. METHODS: Eighteen consecutive early-stage cervical cancer patients scheduled to undergo pelvic lymphadenectomy were included. Prior to surgery, 1.6 mL of 500 µM ICG:HSA or 500 µM ICG alone was injected transvaginally in 4 quadrants around the tumor. The Mini-FLARE imaging system was used for intraoperative NIR fluorescence detection and quantitation. RESULTS: SLNs were identified intraoperatively in 78% of the patients. Patient and tumor characteristics were equally distributed over both treatment groups. No significant difference in signal-to-background ratio (9.3 vs. 10.1, P=.72) or average number of detected SLNs (2.9 vs 2.7, P=.84) was found between the ICG:HSA group and the ICG alone group, respectively. CONCLUSIONS: In conclusion, this double-blind, randomized trial showed no advantage of ICG:HSA over ICG alone for the SLN procedure in early-stage cervical cancer. Further optimization is required to improve the intraoperative detection rate.


Assuntos
Verde de Indocianina , Linfonodos/patologia , Microscopia de Fluorescência/métodos , Biópsia de Linfonodo Sentinela/métodos , Espectroscopia de Luz Próxima ao Infravermelho/métodos , Neoplasias do Colo do Útero/patologia , Adulto , Idoso , Corantes/química , Diagnóstico por Imagem/métodos , Método Duplo-Cego , Feminino , Corantes Fluorescentes/química , Humanos , Verde de Indocianina/química , Raios Infravermelhos , Cuidados Intraoperatórios/métodos , Metástase Linfática , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Albumina Sérica/química , Neoplasias do Colo do Útero/diagnóstico , Neoplasias do Colo do Útero/cirurgia
18.
Ned Tijdschr Geneeskd ; 156(16): A4511, 2012.
Artigo em Holandês | MEDLINE | ID: mdl-22510419

RESUMO

BACKGROUND: Actinomyces is an uncommon cause of infection which can occur in the lower pelvic area in women using an intrauterine device (IUD). The clinical presentation of actinomycosis can easily be confounded with a malignancy. CASE DESCRIPTION: In a 53-year-old woman with abdominal pain and fluctuating temperature, ovarian carcinoma was strongly suspected. She underwent a laparotomy in which both adnexae were removed. Histopathological examination of the specimens revealed, however, a rare Actinomyces infection. The patient received long-term antibiotic therapy in the postoperative period, upon which her condition improved. CONCLUSION: Differentiation between actinomycosis (mycetoma) and a malignancy is difficult. There are few diagnostic tools to demonstrate an Actinomyces infection, and the diagnosis is therefore often not made until during or after operation. The treatment of actinomycosis consists of long-term administration of antibiotics, although combined surgery and antibiotic therapy is often necessary due to the extent of the infection.


Assuntos
Actinomicose/diagnóstico , Doenças Ovarianas/diagnóstico , Actinomicose/tratamento farmacológico , Actinomicose/cirurgia , Antifúngicos/uso terapêutico , Terapia Combinada , Diagnóstico Diferencial , Feminino , Humanos , Pessoa de Meia-Idade , Doenças Ovarianas/tratamento farmacológico , Doenças Ovarianas/cirurgia , Neoplasias Ovarianas/diagnóstico
19.
Am J Obstet Gynecol ; 206(1): 89.e1-5, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21963099

RESUMO

OBJECTIVES: Near-infrared fluorescence imaging has the potential to improve sentinel lymph node mapping in vulvar cancer, which was assessed in the current study. Furthermore, dose optimization of indocyanine green adsorbed to human serum albumin was performed. STUDY DESIGN: Nine vulvar cancer patients underwent the standard sentinel lymph node procedure using (99m)technetium-nancolloid and patent blue. In addition, intraoperative imaging was performed after peritumoral injection of 1.6 mL of 500, 750, or 1000 µM of indocyanine green adsorbed to human serum albumin. RESULTS: Near-infrared fluorescence sentinel lymph node mapping was successful in all patients. A total of 14 sentinel lymph nodes (average, 1.6; range, 1-4) were detected: 14 radioactive (100%), 11 blue (79%), and 14 near-infrared fluorescent (100%). CONCLUSION: This study demonstrates feasibility and accuracy of sentinel lymph node mapping using indocyanine green adsorbed to human serum albumin. Considering safety, cost, and pharmacy preferences, an indocyanine green adsorbed to human serum albumin concentration of 500 µM appears optimal for sentinel lymph node mapping in vulvar cancer.


Assuntos
Carcinoma/patologia , Corantes Fluorescentes , Verde de Indocianina , Linfonodos/patologia , Biópsia de Linfonodo Sentinela/métodos , Espectroscopia de Luz Próxima ao Infravermelho/métodos , Neoplasias Vulvares/patologia , Adulto , Idoso , Carcinoma/diagnóstico por imagem , Relação Dose-Resposta a Droga , Feminino , Humanos , Linfonodos/diagnóstico por imagem , Metástase Linfática , Pessoa de Meia-Idade , Cintilografia , Compostos Radiofarmacêuticos , Agregado de Albumina Marcado com Tecnécio Tc 99m , Neoplasias Vulvares/diagnóstico por imagem
20.
Eur J Obstet Gynecol Reprod Biol ; 160(2): 170-3, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22137982

RESUMO

OBJECTIVE: Comparison of time intervals from diagnosis to chemotherapy between patients opting for embryo cryopreservation or ovarian tissue cryopreservation. STUDY DESIGN: Retrospective analysis. SETTING: University hospital in the Netherlands. PATIENTS AND METHODS: Thirty-five female patients undergoing fertility preservation procedures before treatment with chemotherapy for cancer. Embryo cryopreservation was performed in 12 patients and ovarian tissue cryopreservation in 23 patients. We investigated differences in time intervals (from diagnosis to start of chemotherapy) between patients opting for embryo cryopreservation and patients opting for ovarian tissue cryopreservation. We calculated time intervals between the moment of diagnosis, the moment of referral, the moment of consultation, the moment of finishing of the fertility preservation procedure and the start of chemotherapy. RESULTS: The median time between diagnosis and referral (median=18 days) and between referral and consultation (median=5 days) was comparable in both groups. A significant difference was found between ovarian tissue cryopreservation and embryo cryopreservation for the time interval between consultation and cryopreservation (p=0.001). Ovarian tissue cryopreservation was completed for half of the patients within 6 days after consultation with the gynecologist, and the hormonal stimulation for embryo cryopreservation was completed for all patients within four weeks (median=18 days), with a median of 11 days of hormonal stimulation. A significant difference was found between ovarian tissue cryopreservation and embryo cryopreservation in the time interval between fertility preservation and start of chemotherapy (median=7 vs 19 days, p=0.019). In sum, the total duration between diagnosis and chemotherapy was significantly shorter for ovarian tissue cryopreservation patients than for embryo cryopreservation patients (median=47 vs 69 days, p=0.042). CONCLUSION: Embryo cryopreservation can be performed within the standard timeframe of cancer care in patients with breast cancer receiving adjuvant chemotherapy, but if delay of the start of chemotherapy is harmful, ovarian tissue cryopreservation can be done within one week.


Assuntos
Antineoplásicos/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Carcinoma Ductal de Mama/tratamento farmacológico , Preservação da Fertilidade/métodos , Infertilidade Feminina/induzido quimicamente , Adolescente , Adulto , Antineoplásicos/uso terapêutico , Estudos de Coortes , Criopreservação , Embrião de Mamíferos , Feminino , Hospitais Universitários , Humanos , Países Baixos , Ovário , Encaminhamento e Consulta , Estudos Retrospectivos , Fatores de Tempo , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...